BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
BC Week In Review | Mar 30, 2018
Company News

Takeda mulls Shire takeover

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it is considering a takeout of Shire plc (LSE:SHP; NASDAQ:SHPG), a move the pharma believes would strengthen its core pipeline areas of focus while adding Shire's expertise in rare...
BC Extra | Mar 28, 2018
Company News

Shire posts big gain as Takeda mulls takeover

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it is considering a takeout of Shire plc (LSE:SHP; NASDAQ:SHPG), a move the pharma believes would strengthen its core pipeline areas of focus while adding Shire's expertise in rare...
BC Week In Review | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BC Extra | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Aug 4, 2017
Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
BC Extra | Aug 3, 2017
Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
BC Week In Review | Apr 20, 2017
Clinical News

Vyvanse regulatory update

Shionogi submitted a marketing application in Japan for Vyvanse lisdexamfetamine dimesylate to treat ADHD. In 2011, Shire partnered with Shionogi to co-develop and co-commercialize the prodrug of amphetamine in Japan (see BioCentury, Nov. 21, 2011...
Items per page:
1 - 10 of 263